Compare · DFTX vs MTEX
DFTX vs MTEX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mannatech Incorporated (MTEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTEX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.75B, about 513.5x MTEX ($9.2M).
- Over the past year, DFTX is up 416.0% and MTEX is down 47.3% - DFTX leads by 463.3 points.
- DFTX has hit the wire 8 times in the past 4 weeks while MTEX has been quiet.
- DFTX has more recent analyst coverage (6 ratings vs 0 for MTEX).
PerformanceDFTX+416.01%MTEX-47.31%
2025-08-01+0.00%2026-07-31
- Company
- Definium Therapeutics Inc.
- Mannatech Incorporated
- Price
- $43.50-2.12%
- $4.60-12.30%
- Market cap
- $4.75B
- $9.2M
- 1M return
- +0.24%
- -12.30%
- 1Y return
- +416.01%
- -47.31%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 6
- 0
MTEX
Mannatech Incorporated
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
Latest DFTX
- Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Wells Fargo initiated coverage on Definium Therapeutics with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
Latest MTEX
- SEC Form 4 filed by Chief Financial Officer Haider Yasir
- SEC Form 3 filed by new insider Haider Yasir
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Appointment of Yasir Haider as Chief Financial Officer
- SEC Form 4 filed by Director Toth Robert
- SEC Form 4 filed by Director John Seifrick A
- Mannatech Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Mannatech Announces Results of Annual Shareholders' Meeting
- Director Jobe Larry A bought $11,548 worth of shares (2,803 units at $4.12), increasing direct ownership by 4% to 70,000 units (SEC Form 4)
- Director Jobe Larry A bought $21,000 worth of shares (5,000 units at $4.20), increasing direct ownership by 8% to 67,197 units (SEC Form 4)